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Abstract: Vitamin K (phylloquinone or vitamin K1 and 
menaquinones or vitamin K2) plays an important role as a 
cofactor in the synthesis of hepatic blood coagulation pro-
teins, but recently has also aroused an increasing interest 
for its action in extra-hepatic tissues, in particular in the 
regulation of bone and vascular metabolism. The accurate 
measurement of vitamin K status in humans is still a criti-
cal issue. Along with indirect assays, such as the under-
carboxylated fractions of vitamin K-dependent proteins 
[prothrombin, osteocalcin (OC), and matrix gla protein], 
the direct analysis of blood levels of phylloquinone and 
menaquinones forms might be considered a more inform-
ative and direct method for assessing vitamin K status. 
Different methods for direct quantification of vitamin K 
serum levels are available. High-performance liquid chro-
matography (HPLC) methods coupled with post-column 
reduction procedures and fluorimetric or electrochemical 
detection are commonly used for food and blood analysis 
of phylloquinone, but they show some limitations when 
applied to the analysis of serum menaquinones because 
of interferences from triglycerides. Recent advancements 
include liquid chromatography tandem mass spectro-
metry (LCMS/MS) detection, which assures higher speci-
ficity. The optimization and standardization of these 
methods requires specialized laboratories. The variability 
of results observed in the available studies suggests the 
need for further investigations to obtain more accurate 
analytical results.
Keywords: human health; metabolism; plasma levels; 
vitamin K.
Introduction
Vitamin K has important biological actions, some of which 
are still being discovered. Vitamin K plays a key role in 
the synthesis of several blood coagulation factors, but it is 
also strongly connected to bone metabolism and vascular 
calcifications [1].
Vitamin K exists in two main natural forms: K1 (or 
phylloquinone, PK) and K2 (including several differ-
ent vitamers called menaquinones, MKs) (Figure  1). In 
addition to the naturally occurring phylloquinone and 
menaquinones, there is as a synthetic form of vitamin K: 
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menadione, or vitamin K3 (2-methyl-1, 4-naphthoquinone 
nucleus), representing the basic structure common to 
phylloquinone and menaquinones.
Phylloquinone is mainly found in green vegeta-
bles. The source of menaquinones is more uncertain, 
and although the contribution of the intestinal bacte-
rial flora to vitamin K status is still incompletely under-
stood, the literature indicates that menaquinones are 
derived mainly from intestinal bacteria [2, 3] and fer-
mented food (e.g. cheeses and the Japanese soybean 
product known as ‘natto’) [3]. Liver is also a rich source 
of menaquinones [4].
Menaquinones are classified according to the length 
of their unsaturated side chains. Up to 12 different types 
have been described, from MK-4 to MK-15 [5]. The most 
common MKs in humans are the short-chain MK-4, which 
is the only MK produced by systemic conversion of phyl-
loquinone to menaquinones, and the long-chain vitamers, 
Figure 1: Structures of phylloquinone (vitamin K1) and menaqui-
nones (MKs or vitamin K2).
Menadione (vitamin K3) represents the basic structure common to 
K1 and K2. Menadione is available as a synthetic form of vitamin K.
MK-7 through MK-10, which are synthesized by bacteria in 
humans.
The predominant dietary form of vitamin K in the 
USA, Europe, and most Western countries is phylloqui-
none, while the major form in Japan is menaquinones, 
especially menaquinone 7 (MK-7), which is a component 
of natto [6]. Natto is most popular in the eastern regions 
of Japan, including Kanto, Tohoku, and Hokkaido, but it 
is consumed in all areas.
Different phylloquinone and menaquinones plasma 
concentrations have been reported, with a possible influ-
ence of dietary intake, and a possible analytic interfer-
ence from triglycerides [7]. Mean plasma concentrations 
ranging from 0.22 to 8.88 nmol/L have been reported, 
although in most studies phylloquinone had a concentra-
tion below 2 nmol/L [8].
Daily intake of vitamin K in a Western diet range is 
estimated from 60 μg to 200 μg, of which phylloqui-
none is the larger component (about 90%, versus 10% of 
menaquinones) [9].
Recommendations for daily intake of vitamin K are 
inconsistent. The Institute of Medicine (US) Panel on 
Micronutrients proposed an adequate intake (AI) for men 
and women of 120 and 90 μg/day, respectively, based on 
representative dietary intake data from healthy individu-
als, because of the lack of data to estimate an average 
requirement [10]. Considering that no adverse effect has 
been reported for individuals consuming higher amounts 
of vitamin K, a tolerable upper intake level was not estab-
lished. In 2012, the Italian LARN (Reference Assumption 
Levels for Nutrients and Energy), proposed by the Human 
Nutrition Italian Society (SINU), suggested an intake of 
vitamin K stratified for age (140 or 170 μg/day for 18–59 
and > 60  years old, respectively). However, in the 2014 
release of the same recommendations this group stated 
that the available evidence does not allow to define the 
adequate intake for vitamin K [11]. In the UK, a government 
backed panel of experts pointed out that although vitamin 
K is known to be essential, recommendations on adequate 
nutritional intakes have not been precisely established, 
because of the unquantified contribution made by the 
intestinal bacteria [12]. They reported previous data of 
daily intake suggested by the UK Department of Health’s 
Committee on Medical Aspects of Food Policy (COMA): 1 
μg/kg body weight [13], which is probably adequate for 
blood clotting, but suboptimal for bone health. Vitamin 
K is required to introduce carboxyl groups into glutamic 
acid residues in four of the blood coagulation factors 
(II, VII, IX, X) to yield γ-glutamic carboxyl (Gla) residues 
(Figure 2), while vitamin K hydroquinone is transformed 
into vitamin K 2,3-epoxide [14]. Importantly, warfarin 
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interferes with regeneration of vitamin K 2,3-epoxide to 
vitamin K hydroquinone, thus impairing γ-carboxylation 
and the activity of vitamin K dependent proteins, includ-
ing the extra-hepatic proteins OC (bone Gla-protein; BGP) 
and matrix Gla-protein (MGP), respectively involved in 
bone mineralization and inhibition of vascular calcifi-
cations. If vitamin K is deficient, vitamin K dependent 
proteins cannot increase their carboxylation status (and 
they become significantly undercarboxylated), losing 
their capacity to bind calcium, so that bone metabolism 
may be impaired and the process of vascular calcification 
enhanced [15].
Both phylloquinone and MKs may activate the steroid 
and xenobiotic receptor (SXR). SXR is a nuclear receptor 
involved in the transcriptional regulation of enzymes such 
as cytochrome P450 (in particular the CYP3A4 isoform) 
[16]. SXR and its murine ortholog, pregnane X receptor 
(PXR), are nuclear receptors that are expressed at high 
levels in the liver and the intestine. They work as xenobi-
otic sensors that induce expression of genes involved in 
detoxification and drug excretion, but they were recently 
shown to be also expressed in osteoblasts and involved 
in bone metabolism [17]. Hydroxylation of vitamin K is 
catalyzed by cytochrome P450 enzymes, which often are 
induced by their substrates themselves via the activation 
of the nuclear receptor PXR [18].
Azuma et al. described the osteopenic phenotype of 
systemic PXR knockout mice; they observed a remark-
able reduction of width and an important gap between 
femoral and tibial articular cartilages in PXR knockout 
mice, resulting in aging-dependent wearing of knee joints 
articular cartilage. These findings may indicate that SXR/
PXR protects against aging-dependent wearing of articu-
lar cartilage and that ligands for SXR/PXR have a poten-
tial role in preventing osteo-articular diseases caused by 
aging [19].
Metabolism of vitamin K: general 
principles
Most of our knowledge on the metabolism of vitamin 
K  –  in particular about its intestinal absorption, trans-
port, cellular uptake and catabolism – is related to phyl-
loquinone, while data about menaquinones are more 
limited [2]. Vitamin K forms derived from plants and bac-
teria have a poorer bioavailability than those contained 
in oil-based and processed foods. Low plasma concen-
trations of phylloquinone reflect low tissue reserves. 
Vitamin K tissue concentrations have been determined. 
In adults, phylloquinone concentrations are about 10 
pmol/g-wet tissue in liver, hearth and pancreas, while 
they are lower in brain, kidney and lung (> 2 pmol/g). 
Contrariwise, high MK-4 concentrations were found in 
human brain and kidney (6 pmol/g) and even higher in 
pancreas (22  pmol/g) than in other tissues, such as in 
plasma and liver [20].
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Figure 2: The vitamin K cycle and the interference of warfarin with vitamin K recycling.
Gla-proteins are carboxylated by a specific vitamin K dependent carboxylase, through several rounds of carboxylation. Here a single round of 
carboxylation is depicted. (Reprinted with permission from Fusaro et al. [15].) ucVKD-proteins,  undercarboxylated vitamin K dependent proteins.
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Considering that MK-4 derives from the endogenous 
conversion of phylloquinone, the specific tissue distribu-
tion of MK-4 is suggestive of local synthesis from phyl-
loquinone. MK-4 is synthetized in testes, pancreas and 
blood vessels. In particular, the conversion of phylloqui-
none into MK-4 occurs either directly or by interconver-
sion to menadione (K3), followed by prenylation to MK-4 
[21]. Therefore, the biological activity of K3 is entirely 
dependent on its prenylation to MK-4.
However, the molecular mechanisms of conversion 
remain unclear. Nakagawa et al. identified a human MK-4 
biosynthetic enzyme known as UbiA prenyltransferase 
containing 1 (UBIAD1), by screening the human genome 
database. UBIAD1 is localized in the endoplasmic reticu-
lum and ubiquitously expressed in several mouse tissues. 
Short interfering RNA against the UBIAD1 gene inhibited 
the conversion of deuterium-labeled phylloquinone mol-
ecules into deuterium-labeled-MK-4 (MK-4-d7) in human 
cells. An additional proof that the UBIAD1 gene encodes 
an MK-4 biosynthetic enzyme derives from its expres-
sion in cells infected with UBIAD1 baculovirus, which 
can convert deuterium-labeled vitamin K derivatives into 
MK-4-d7 [22].
Phylloquinone is probably converted into MK-4 within 
the tissues themselves, rather than via hepatic meta-
bolism. After phylloquinone administration, the MK-4 
concentration increased much more slowly in each of the 
tissues than that of phylloquinone, and the MK-4 concen-
tration in plasma and liver reached much lower levels 
than those observed in other tissues [23].
Vitamin K is transported in plasma by lipoproteins 
[24]. After digestion in the intestinal tract, dietary vitamin 
K and triglycerides (TG) are emulsified by bile salts to form 
mixed micelles in the enterocytes and processed into chy-
lomicrons (CR), containing apolipoprotein A (apoA) and 
apoB, and then secreted into the lymph ducts and blood 
circulation. CR are modified peripherally, in adipose or 
muscular tissues, by the action of lipoprotein lipase (LPL) 
and re-enter in the circulation, but they continue trans-
porting vitamin K in their lipophilic core [25].
The uptake of vitamin K into the liver seems to follow 
the same pathway of lipoprotein [26]. In fact, CR enter into 
the liver by endocytosis and they are processed to finally 
obtain smaller LDL molecules; vitamin K is presumed to 
remain still located in the lipophilic core of lipoproteins.
Concerning the uptake of vitamin K into bone tissue 
[27], it is known that osteoblasts obtain most of their phyl-
loquinone by CR pathway and most of their MK-7 by LDL 
pathway. Osteoblasts express lipoprotein receptors, which 
interact with CR and LDL and start the process of endocy-
tosis of the particles and the vitamin K.
The liver is also the site of vitamin K catabolic pathway, 
common to phylloquinone and MKs. The poly-isoprenoid 
side chains are shortened, undergoing ω-oxidation fol-
lowed by β-oxidation leading to two major aglycone metab-
olites with side chain lengths of five and seven carbon 
atoms (5C and 7C metabolites, respectively). Finally, after 
conjugation with glucuronic acid, the metabolites are 
excreted in the bile and urine, mainly as glucuronides [2].
Review of the assessment of 
vitamin K status and the possible 
role of vitamin K plasma levels 
measurement
One barrier to gaining a better understanding of vitamin 
K function has been the difficulty in developing methods 
for the measurement of vitamin K. Vitamin K was the last 
of the four fat-soluble vitamins to be measured at endog-
enous levels. The degree of this analytical challenge is a 
consequence of vitamin K being the most lipophilic and 
least abundant of the fat soluble vitamins. These proper-
ties do not easily lend themselves to the development of 
assays suitable for current generation automated chemis-
try platforms, unlike vitamin D.
Vitamin K status can be assessed by indirect func-
tional tests such as the prothrombin time or by measure-
ment of undercarboxylated proteins (Table 1), such as OC 
and matrix Gla protein (MGP), which are more sensitive 
in detecting subclinical vitamin K deficiency than pro-
thrombin time [28]. The amount of undercarboxylated 
OC could represent a sensitive marker of vitamin K status 
in humans [29]. However, although a high percentage of 
undercarboxylated OC indicates poor vitamin K status, 
this value better reflects recent vitamin K intake and not 
the long-term vitamin K status.
Osteocalcin levels are also influenced by vitamin D, 
which is required for the production of undercarboxy-
lated OC, whereas vitamin K is required for the conversion 
of undercarboxylated to mature OC. Data from healthy 
volunteers indicate a weak but significant correlation 
between undercarboxylated OC and vitamin D, suggest-
ing that the serum level of undercarboxylated OC may 
be an insufficiently reliable marker for vitamin K status 
[30]. OC is also influenced by PTH, which is significantly 
elevated in many CKD patients. Therefore, CKD patients 
with hyperparathyroidism will present high serum uOC, 
but this does not necessarily mean that they are vitamin 
K deficient.
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Undercaboxylated unphosphorylated MGP 
(ucdpMGP), the inactive form of MGP, may be a good 
alternative to evaluated vitamin K status of the subjects; 
Indeed, randomized controlled studies have shown that 
vitamin K therapy decreases ucdpMGP levels [31–34]. 
Moreover, AVK treatment increased the amount of inactive 
ucdpMGP [35, 36]. Stopping that treatment has also been 
shown to decrease ucdpMGP [37]. All these date suggest 
that ucdpMGO could be a good marker of vitamin K status. 
However, ucdpMGP determination is only available on the 
automated IDS iSYS instrument, which is not available 
everywhere. Moreover, measuring inactive MGP may only 
reflect the vitamin K status at the vascular level and not 
at other organ’s levels (in particular bone and liver). In 
this context, direct measurement of vitamin K could be of 
interest by its own, or in combination with ucdpMGP.
Moreover, protein induced in vitamin K absence 
(PIVKA-II) could be a sensitive marker to predict mild 
vitamin K deficiency, as reported among newborns. 
PIVKA-II is an inactive precursor of prothrombin and is 
elevated in vitamin K deficiency [38].
Urinary vitamin K metabolites can be measured in 
the urine. Harrington et al. tested this analytic approach 
in young adults [39] and studied its clinical significance 
in the pediatric population [40]. Urinary excretion of 
7C-aglycone and 5C-aglycone, vitamin K metabolites 
common to both phylloquinone and the menaquinone 
series, were assessed following restriction or supple-
mentation with phylloquinone. Results indicate a good 
relationship of urinary metabolites with dietary phylloqui-
none intake. In newborns, vitamin K urinary metabolites 
excretion was 25 times lower than adults and improved 
after prophylaxis. Infants mainly excreted 5C-aglycone, 
while increased excretion of the 7C-aglycone was associ-
ated with metabolic overload because of the exposure to 
high-tissue phylloquinone concentrations. Measurement 
of the 5C- and 7C-aglycones was therefore proposed as a 
good approach to study vitamin K status in neonates and 
as an aid the development of improved prophylactic regi-
mens [40]. Urinary vitamin K metabolites have not been 
studied in CKD patients, but deterioration of renal func-
tion might interfere with the reliability of this marker of 
vitamin K status.
Determination of vitamin K plasma 
levels: technical aspects
Providing a standardized measurement of plasma levels of 
vitamin K forms, in particular for some MKs, is challeng-
ing. Measuring vitamin K in plasma is difficult because 
of the low circulating vitamin K levels and the non-polar 
characteristics of vitamin K as well as the interference of 
lipids [41].
Different methods for direct quantification of 
vitamin K serum levels have been developed and evalu-
ated (Table 1). High-performance liquid chromatography 
(HPLC) is considered the elective technique to measure 
vitamin K subtypes.
HPLC has been developed starting from the second 
half of the last century [42], then extended to the meas-
urement of long-chain MKs in the late 1980s [43]. Ini-
tially, HPLC with ultraviolet detection (UV) was used to 
Table 1: Measurement of vitamin K status in humans: summary of direct and indirect methods.
Methods   Main characteristics
Indirect methods
  Prothrombin time   Cannot be used as a reliable indicator of vitamin K status
  Undercarboxylated osteocalcin (ucOC) or matrix Gla protein 
(ucMGP)
  Vitamin K deficiency is associated with reduced carboxylation of vitamin 
K dependent proteins and higher levels of ucOC and ucMGP. Vitamin D 
regulates osteocalcin gene expression
  PIVKA-II   Elevated in vitamin K deficiency
  Urinary vitamin K metabolites (7C-aglycone and 5C-aglycone)   Vitamin K metabolites mainly tested in pediatric population
Direct methods
  High-performance liquid chromatography (HPLC) with 
ultraviolet (UV) detection
  Lower sensitivity and selectivity
  HPLC with fluorescence detection   Provides greater sensitivity and selectivity than UV detection. Most 
common method used in laboratories
  HPLC with electrochemical detection (ECD)   Post-column reduction is used to convert the quinone structure of vitamin K 
in the corresponding hydroquinones, measured in oxidation mode
  Liquid chromatography tandem mass spectrometry 
(LC-APCI-MS/MS)
  Provides higher sensitivity and selectivity in comparison with other 
techniques
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determinate PK plasma concentration. Afterwards, HPLC 
with fluorescence after post column reduction demon-
strated greater sensitivity and selectivity than UV method 
[44, 45], but it required extensive sample pre-purification 
to reduce the chromatographic interference induced by 
lipids [41].
Other recent methods for determination of PK and 
MKs are based on liquid chromatography tandem mass 
spectrometry (LCMS/MS), which present higher sensi-
tivity and selectivity, but they require longer analytical 
times. Suhara et al. [46] developed a model of liquid chro-
matography-tandem mass spectrometry (LC-APCI-MS/MS) 
method for the measurement of vitamin K plasma levels 
(PK, MK-4, and MK-7), characterized by high sensitivity 
and selectivity. However, the method is excessively long 
for routine analysis, because of the pre-purification pro-
cedure is based on dual step extraction, chromatographic 
separation followed by a wash and re-equilibration period. 
Gentili et al. simplified the process and reduced the total 
run-time [47]. With this method, MK-4 and MK-7 levels 
were undetectedable in the analyzed serum samples of 
subjects on a Mediterranean diet [47]. Karl et al. [48] devel-
oped a method employing HPLC-mass spectrometry with 
atmospheric pressure chemical ionization (LC-APCI-MS) 
for simultaneous quantification of 11 vitamin K vitamers, 
which was applied to biological samples such as serum, 
faeces and food. They suggested that the method can be 
applied in human and animal studies examining the role 
of vitamin K vitamers derived from the diet and gut bacte-
ria synthesis in health and disease.
Riphagen et  al. [49] also described a method based 
on LC-APCI-MS/MS with atmospheric pressure chemical 
ionization to detect plasma PK, MK-4 and MK-7 levels, sim-
plifying the sample pre-purification process and reducing 
the total run-time without compromising sensitivity and 
selectivity. In a study population of 60 renal transplant 
recipients, the authors confirmed that plasma PK con-
centrations were significantly associated with recent PK 
dietary intake and plasma MK-4 concentrations, and that 
plasma vitamin K levels were strongly correlated with 
plasma triglyceride concentrations [49].
It is known that vitamin K is mainly transported by 
triglyceride-rich lipoproteins [50]. This is a critical point to 
consider for obtaining a reliable determination of vitamin 
K serum levels, because the interaction of the lipoprotein 
and the HPLC-column may affect the sample purification 
and measurement.
Considering that UV and fluorimetric detectors appear 
to be largely inadequate, selective and sensitive analysis of 
all the vitamin K subtypes can be also achieved by electro-
chemical detection (ECD), using small samples containing 
low vitamin K concentrations [51]. During ECD, post-col-
umn reduction is used to convert the quinone structure of 
vitamin K in the corresponding hydroquinones, measured 
in oxidation mode. This reduction is operated by zinc or 
platinum. Reduction can also be achieved electrochemi-
cally, through a dual electrode approach [52].
In the VIKI study [53], taking into account the con-
nection between the lipid plasma content and the chro-
matography resolution, the authors who performed the 
laboratory analyses used a simple, sensitive and selective 
reversed phase HPLC method for determination of vitamin 
K subtypes in human plasma. The method followed the 
principle of redox mode electrochemical detection based 
on Wakabayashi’s technology [52]. It is characterized by a 
liquid-liquid extraction, followed by a solid-phase extrac-
tion of human plasma using polymeric reversed phase 
cartridges; the MKs were measured by an electrochemi-
cal detector after post-column reduction with platinum 
on alumina powder and using the MK-8 form as internal 
standard. The method was able to reduce the percent-
age of bad chromatogram resolution in plasma of dialy-
sis patients, which is often characterized by increased 
total cholesterol and triglycerides concentrations. The 
authors also observed that some vitamer concentrations 
resulted higher than the normal reference value previ-
ously reported in literature [53].
Because of the complexity of plasma vitamin K 
determination and of possible analytical errors, external 
quality assurance services could be useful to verify and 
harmonize results from different laboratories. One exter-
nal quality assurance service (KEQAS) for circulating 
phylloquinone analysis is already active [54].
Determination of vitamin K levels: 
clinical issues
A large variability of vitamin K levels has been observed 
in humans [8]. In addition to the analytical variability, 
dietary and individual factors influence plasma levels 
of vitamin K subtypes. Most studies assessed circulating 
vitamin K in relation to dietary vitamin K intake, and a 
smaller but significant number of studies evaluated the 
association of vitamin K levels with chronic diseases. Cur-
rently, there is not a consensus on a plasma vitamin K 
level indicating deficiency or insufficiency. Similarly, it is 
not clear which vitamer should be considered as reference 
for determining the vitamin K status. Most studies have 
addressed the coagulation system, but other outcomes, 
especially bone metabolism and vascular calcifications, 
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are clinically relevant and might behave differently with 
respect to plasma PK or MKs.
Data obtained in healthy subjects and osteoporotic 
patients supplemented with MK-4 showed a large vari-
ability of vitamin K levels. In healthy subjects, levels of 
MK-4, PK and MK-7 (reported as ng/mL and mean ± SD) 
were 0.15 ± 0.17, 1.81 ± 1.10 and 16.27 ± 20.58, respectively, 
while in osteoporotic patients receiving MK-4, these levels 
were 46.83 ± 46.41, 0.62 ± 0.25 and 4.18 ± 6.28, respectively 
[42]. The influence of supplementation on MK-4 levels was 
also observed in another study [55], in contrast with the 
low MK-4 bioavailability reported in humans by Sato [56].
Variability of menaquinones levels has also been 
reported in a Japanese study in post menopausal women 
(5.26 ± 6.13 ng/mL in the Tokyo area, where natto is largely 
consumed vs. 1.22 ± 1.85 in the western Japanese area), 
indicating that the geographic difference in MK-7 levels 
may be ascribed to natto intake. In this study, the authors 
observed an inverse correlation between natto consump-
tion and fracture risk, suggesting the possibility that natto 
intake might contribute to reduce fractures by increasing 
MK-7 levels [6].
Other authors measured phylloquinone levels, dem-
onstrating that vitamin K deficiency affects 24% of the 
general population and 29% of hemodialysis patients 
[57, 58].
The impact of vitamin K on human health (Table  2) 
has become more and more relevant, considering the 
Table 2: Main vitamin K actions in humans.
–  Regulation of blood coagulation activity
–  Bone protection; prevention of osteoporosis and bone fracture
–  Prevention of vascular calcifications
–  Prevention of cancer
–  Prevention of inflammation
Table 3: Consequences of inhibition of vitamin K-dependent proteins.
Coagulation   Prothrombin (factor II)   Bleeding
  VII, IX, X factors  
  Protein C, S, Z  
Vessels   MGP   Vascular calcifications
  Osteocalcin  
  GAS-6  
Bone   Osteocalcin   Inadequate bone mineralization
  MGP   Bone fractures
  Periostin  
Cellular proliferation   GAS-6   Action on cellular proliferation, cellular adhesion, inhibition of apoptosis
Others: Inflammation   Not defined   Increase of inflammation
MGP, matrix Gla protein; BGP, bone Gla protein; GAS, growth arrest specific gene.
evidence of vitamin K biological actions in bone meta-
bolism and cardiovascular disease, exceeding its better 
known involvement in the blood coagulation system [59], 
as reported in Table 3.
Several studies suggest that low vitamin K levels are 
related to osteoporosis, pathological fractures and vas-
cular calcifications. Supplementing MK-7 at the dose of 
at least 200 μg per day might help protecting from vas-
cular calcification, osteoporosis and cancer [60]. More-
over, supplementation of 5  mg daily phylloquinone in 
440 postmenopausal women with osteopenia for 2 years 
in a randomized, placebo-controlled, double-blind trial 
caused a > 50% reduction in clinical fractures vs. placebo, 
although no protection against the age-related decline in 
bone mineral density was observed [61].
A meta-analysis has shown that in seven Japanese 
trials reporting fractures, menaquinones administration 
significantly reduced the risk of hip (77% reduction), ver-
tebral (60% reduction) and all non-vertebral fractures 
(81% reduction) [62].
Vitamin K administration also significantly delayed 
the progression of coronary artery calcifications and the 
deterioration of arterial elasticity [63]. A lower risk of 
coronary heart disease and severe aortic calcifications 
was observed with higher menaquinones intake, but not 
with phylloquinone intake. This finding suggests that the 
dietary phylloquinone intake, without menaquinones, 
may not be sufficient to suppress arterial calcifications 
[64, 65].
Menaquinones have been shown to play an important 
role also in cancer. In a small (40 patients) randomized 
study the administration of menaquinones 45  mg/day 
reduced the development of hepatocellular carcinoma in 
patients with liver cirrhosis: the risk ratio for the devel-
opment of hepatocellular carcinoma in patients given 
menaquinones was 0.13 [66].
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Menaquinones have additional properties in certain 
cell and tissue types, particularly in bone tissue and in the 
immune system. Much of the available evidence relates 
specifically to MK-4, which was found to have a role in 
bone health since the 1990s. Low circulating levels of 
menaquinones are associated with osteoporotic fractures 
in the elderly [67], and menaquinones improved bone 
mineral density in Japanese women [68]. In an experi-
mental setting, MK-4 reduced bone losses caused by 
either oestrogen withdrawal or corticosteroid treatment 
in experimental model on rats [69, 70]. Moreover, other in 
vitro studies showed that MK-4 inhibits the synthesis of 
prostaglandin E2 (PGE2), a bone reabsorption-inducing 
agent, in cultured osteoblasts [71], and inhibits the for-
mation of osteoclast-like cells in bone marrow-derived 
cultures [72]. Finally, experimental data suggests a possi-
ble role of MK-4 on pancreatic exocrine cells metabolism. 
Stimulation of pancreatic acinar cells with secretagogues 
cholecystokinin-8 and secretin induces secretion of MK-4, 
along with phospholipase and the membrane trafficking 
protein caveolin-1 [73], although a well-defined function 
of MK-4 in this setting remains unclear.
The frequent use of warfarin enhances the problem 
of vitamin K deficiency and its role on bone and vascu-
lar disease [74]. Warfarin may predispose to bone frac-
tures and vascular calcification by different mechanisms: 
directly, by inhibition of γ-carboxylation of OC and other 
bone matrix proteins; indirectly, because patients treated 
with warfarin may limit their dietary intake of foods rich 
in vitamin K. New oral anticoagulant seems to have less 
influence on bone metabolism, but their long-term effects 
need more studies [75, 76].
In the VIKI study [53], a comprehensive assessment of 
vitamin K status was carried out in a cohort of  hemodialysis 
patients and in healthy controls, including most vitamin K 
subtypes (in particular PK, MK-4, MK-5, MK-6, and MK-7), 
adjusted for triglycerides levels. Vitamin K deficiency was 
found in 35.4% of hemodialysis patients for MK-7, 23.5% 
for PK and 14.5% for MK-4. With the limitations of its 
observational nature, this is the first study to relate phyl-
loquinone and menaquinones deficiency directly both to 
vertebral fractures and vascular calcification in the dialy-
sis population. In particular, phylloquinone deficiency 
was the strongest predictor of vertebral fractures, while 
lower MK-4 and MK-7 levels were associated with vas-
cular calcification. The results in  hemodialysis patients 
may point out a possible role of vitamin K deficiency as 
a cause of bone and vascular disease also in the general 
population. We can hypothesize that a diet rich in vitamin 
K and/or vitamin K supplements might be of help in pre-
venting bone disease and avoiding vascular calcifications, 
opening interesting perspectives for research in human 
health.
Finally, vitamin K status was found to be inversely and 
significantly related to individual inflammatory markers 
and to the inflammatory process in a human population 
study based on the Framingham Offspring Study cohort 
[77]. This finding is supported by studies on rats demon-
strating that animals with vitamin K-deficient diets had an 
enhanced expression of genes involved in acute inflam-
matory response compared to those with normal or phyl-
loquinone-supplemented diets and that a supplemented 
diet suppressed the inflammatory response [78].
Conclusions
There is no homogeneity of data about vitamin K plasma 
levels in healthy subjects. As dietary analytical, nutri-
tional and metabolic factors play an important role, 
further investigations are necessary to provide more infor-
mation on vitamin K status.
In this review, we analyzed the literature regarding 
the validity of direct measurement of vitamin K levels. 
Vitamin K is a molecule with non-polar characteristics and 
lipids, in particular triglycerides, interfere with vitamin K 
measurement. Sample preparation for vitamin K analysis 
remains difficult and requires highly specialized laborato-
ries. In addition, circulating vitamin K levels are markedly 
lower than those of other lipophilic vitamins.
Indeed, not necessarily direct measurement of vitamin 
K plasma levels are superior to the assessment of vitamin 
K status through measurement of undercarboxylated frac-
tions of vitamin K dependent proteins, which could better 
represent the functional status of the protein. However, 
if we recognize that phylloquinone and menaquinones 
have different actions, carboxylation status of vitamin K 
dependent proteins might not distinguish the respective 
roles of the two forms of vitamin K. Thus, developing better 
analytical techniques for direct vitamin K determination 
is certainly desirable for improving selective therapies for 
menaquinones associated bone and vascular diseases.
Currently, an effective analytical method for assess-
ing circulating vitamin K appears to be the one described 
by Riphagen et al. [49], a liquid chromatography tandem 
mass spectrometry method for determination of three 
vitamers (PK, MK-4, and MK-7) with a simplified sample 
pre-purification process and reduced total run-time. 
Hopefully, this assay should avoid the interference by cir-
culating triglycerides and should allow the identification 
of all vitamin K subtypes.
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Further efforts are needed for developing a single, 
rapid and standardized method for evaluating vitamin K 
plasma levels.
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